Semaglutide cuts risk for kidney outcomes, death in CKD with T2DM
May 31, 2024
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.
Coverage for Medicare’s e-visits still available, though few patients use service
By
Kristen Fischer
Apr 16, 2024
E-visits, which drew expanded coverage during the pandemic still are available but not used often, a new study shows.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
Diabetes increases risk for functional limitations in older adults
May 03, 2024
The findings were seen even after controlling for sociodemographic and other health factors.
In trial, researchers test EHR alerts to lower harmful screenings, overtreatment in seniors
By
Kristen Fischer
Feb 15, 2024
Researchers devised a new way to ensure that older adults aren’t being overtreated or tested needlessly via unnecessary screenings.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
Fresh, delivered produce tied to improvements in CVD risk factors
Mar 22, 2024
Significant improvements were seen for produce consumption, physical activity, non-high-density lipoprotein cholesterol and HbA1c.
Position statement addresses optimal management of diabetes
Feb 21, 2024
Tools available to help healthcare providers include guided communication styles and clinical screening tools for psychosocial conditions.
Exercise intensity, duration can affect CKD risk in obesity, type 2 diabetes
Feb 07, 2024
An inverse link was seen for total moderate-to-vigorous physical activity and MVPA accumulated in bouts of ≥10 minutes with progression to chronic kidney disease in overweight/obese adults with type...
ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.